Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2425 USD | -6.69% | +3.90% | -88.56% |
Mar. 28 | Transcript : ENDRA Life Sciences Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
Mar. 28 | ENDRA Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 1M | Sales 2025 * | - | Capitalization | 2.68M |
---|---|---|---|---|---|
Net income 2024 * | -12M | Net income 2025 * | - | EV / Sales 2024 * | 2.68 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.17
x | P/E ratio 2025 * |
-
| Employees | 21 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.85% |
Latest transcript on ENDRA Life Sciences Inc.
1 day | -6.69% | ||
1 week | +3.90% | ||
Current month | -58.19% | ||
1 month | -73.35% | ||
3 months | -76.46% | ||
6 months | -75.26% | ||
Current year | -88.56% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 14-12-31 | |
Irina Pestrikova
DFI | Director of Finance/CFO | 38 | 21-06-17 |
Michael Thornton
CTO | Chief Tech/Sci/R&D Officer | 55 | 06-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 13-06-30 | |
Alexander Tokman
BRD | Director/Board Member | 62 | 07-12-31 |
Michael Harsh
BRD | Director/Board Member | 69 | 14-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 0.2425 | -6.69% | 35,436 |
24-04-24 | 0.2599 | +2.16% | 42,059 |
24-04-23 | 0.2544 | +1.68% | 37,025 |
24-04-22 | 0.2502 | +1.30% | 18,144 |
24-04-19 | 0.247 | +5.83% | 67,593 |
Delayed Quote Nasdaq, April 25, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-88.56% | 2.68M | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+45.26% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- NDRA Stock